Lonza Highlights Cutting-Edge Clean-Label Solutions to Welcome a Healthy Future at Natural Products
Expo East 2019
Lonza showcases expanding portfolio of clean-label solutions at Natural Products Expo East 2019, booth 3238, Baltimore, MD (USA), 12-14 September 2019
Vcaps® Plus Natural Colors capsule and other vegetarian dosage forms to be highlighted
Innovative clean-label ingredients, including Lonza’s proprietary Oceanix™ and ResistAid® will also be on display
Basel, Switzerland, 13 August 2019 – Lonza will highlight its innovative range of clean-label ingredients, dosage forms and delivery systems at Natural Products Expo East 2019 in Baltimore, MD (USA). Designed to help manufacturers meet the growing demand for naturally-derived supplement products, Lonza’s expanding portfolio — which will be on showcase at booth 3238 — offers clean-label solutions for a range of health applications, including sports performance and immune support.
The demand for natural, plant-based and vegetarian and vegan products continues to grow in the dietary supplements space. Lonza’s range of high-quality vegetarian capsules has proven successful in supporting customers to overcome both labeling requirements and formulation challenges as the clean-label trend evolves.
As a pioneer in high performance capsules, Lonza continues to bring new clean-label innovations to the US market. At the show, the team will showcase Lonza’s vegetarian Vcaps® Plus capsules, made from hypromellose (HPMC) and water only. Thanks to the latest advances in coloring foods, the Vcaps® Plus capsules can now also be tinted to create bright, vibrant supplement products, without compromising on a clean-label positioning. The next-generation Vcaps® Plus Purple Carrot capsules open up new possibilities for Lonza’s customers in the supplements space, while also maintaining a natural appearance and delivering improved supply chain transparency.
Solutions in Lonza’s plant-based range also include its innovative dosage forms, such as its vegetarian Plantcaps® capsules. Made from pullulan obtained from tapioca via a natural fermentation process, Lonza’s Plantcaps® capsules offer a superior oxygen barrier to help protect sensitive ingredients. Its DRcaps™ capsules, enabling the timed release of ingredients, will also be showcased.
Meeting Market Demand
With the sports nutrition market projected to reach $14 billion by 2023, natural, plant-based sports nutrition products are becoming more popular as the clean-label trend gains traction in this category.
Highlighting its expertise in the performance nutrition space, Lonza will showcase its Oceanix™ marine phytoplankton brand. The clean-label Oceanix™ supports peak physical performance and faciliates an increased physiological response against oxidative stress to aid recovery. Supplying high levels of superoxide dismutase (SOD), Oceanix™ harnesses all the natural goodness of marine phytoplankton (Tetraselmis chuii) in a small, concentrated dose of 25 mg/day.
Visitors to Lonza’s booth can also discover its scientifically backed ResistAid® for immune support. Extracted from North American Larch Trees using a steam-only process, the proprietary ResistAid® (larch arabinogalactan) offers year-round immune benefits.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
 Euromonitor Consumer Health and Nutrition database, 2019.
Lonza Contact Details
Dr. Kristin Koehler
Lonza Group Ltd
Tel +41 61 316 8782
Dr. Sanna Fowler
Head of Public Relations
Lonza Pharma & Biotech
Tel +41 61 316 8929
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.